Cargando…
Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management
Ovarian cancer patients with homologous recombination deficiencies exhibit specific clinical behaviors, and improved responses to treatments, such as platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors, have been observed. Germline mutations in the BRCA 1/2 genes are the m...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096977/ https://www.ncbi.nlm.nih.gov/pubmed/30133561 http://dx.doi.org/10.6061/clinics/2018/e450s |
_version_ | 1783348210506399744 |
---|---|
author | da Cunha Colombo Bonadio, Renata Rodrigues Fogace, Rodrigo Nogueira Miranda, Vanessa Costa Diz, Maria del Pilar Estevez |
author_facet | da Cunha Colombo Bonadio, Renata Rodrigues Fogace, Rodrigo Nogueira Miranda, Vanessa Costa Diz, Maria del Pilar Estevez |
author_sort | da Cunha Colombo Bonadio, Renata Rodrigues |
collection | PubMed |
description | Ovarian cancer patients with homologous recombination deficiencies exhibit specific clinical behaviors, and improved responses to treatments, such as platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors, have been observed. Germline mutations in the BRCA 1/2 genes are the most well-known mechanisms of homologous recombination deficiency. However, other mechanisms, such as germline and somatic mutations in other homologous recombination genes and epigenetic modifications, have also been implicated in homologous recombination deficiency. The epidemiology and implications of these other mechanisms need to be better understood to improve the treatment strategies for these patients. Furthermore, an evaluation of various diagnostic tests to investigate homologous recombination deficiency is essential. Comprehension of the role of homologous recombination deficiency in ovarian cancer also allows the development of therapeutic combinations that can improve the efficacy of treatment. In this review, we discuss the epidemiology and management of homologous recombination deficiency in ovarian cancer patients. |
format | Online Article Text |
id | pubmed-6096977 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo |
record_format | MEDLINE/PubMed |
spelling | pubmed-60969772018-08-20 Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management da Cunha Colombo Bonadio, Renata Rodrigues Fogace, Rodrigo Nogueira Miranda, Vanessa Costa Diz, Maria del Pilar Estevez Clinics (Sao Paulo) Review Article Ovarian cancer patients with homologous recombination deficiencies exhibit specific clinical behaviors, and improved responses to treatments, such as platinum-based chemotherapy and poly (ADP-ribose) polymerase (PARP) inhibitors, have been observed. Germline mutations in the BRCA 1/2 genes are the most well-known mechanisms of homologous recombination deficiency. However, other mechanisms, such as germline and somatic mutations in other homologous recombination genes and epigenetic modifications, have also been implicated in homologous recombination deficiency. The epidemiology and implications of these other mechanisms need to be better understood to improve the treatment strategies for these patients. Furthermore, an evaluation of various diagnostic tests to investigate homologous recombination deficiency is essential. Comprehension of the role of homologous recombination deficiency in ovarian cancer also allows the development of therapeutic combinations that can improve the efficacy of treatment. In this review, we discuss the epidemiology and management of homologous recombination deficiency in ovarian cancer patients. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2018-08-03 2018 /pmc/articles/PMC6096977/ /pubmed/30133561 http://dx.doi.org/10.6061/clinics/2018/e450s Text en Copyright © 2018 CLINICS http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited. |
spellingShingle | Review Article da Cunha Colombo Bonadio, Renata Rodrigues Fogace, Rodrigo Nogueira Miranda, Vanessa Costa Diz, Maria del Pilar Estevez Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management |
title | Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management |
title_full | Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management |
title_fullStr | Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management |
title_full_unstemmed | Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management |
title_short | Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management |
title_sort | homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096977/ https://www.ncbi.nlm.nih.gov/pubmed/30133561 http://dx.doi.org/10.6061/clinics/2018/e450s |
work_keys_str_mv | AT dacunhacolombobonadiorenatarodrigues homologousrecombinationdeficiencyinovariancancerareviewofitsepidemiologyandmanagement AT fogacerodrigonogueira homologousrecombinationdeficiencyinovariancancerareviewofitsepidemiologyandmanagement AT mirandavanessacosta homologousrecombinationdeficiencyinovariancancerareviewofitsepidemiologyandmanagement AT dizmariadelpilarestevez homologousrecombinationdeficiencyinovariancancerareviewofitsepidemiologyandmanagement |